The IL-4Rα signaling promotes barrier-altering oncostatin M and IL-6 production in AERD

This study showed for the first time that nasal fluid levels of oncostatin M (OSM) and IL-6 are higher in AERD patients compared to healthy controls and are reduced by dupilumab treatment. We suspect that one of the reasons that dupilumab works so well as a treatment for AERD nasal polyps might be because it reduces those levels of OSM and IL-6 (in addition to its ability to reduce other “Type 2” inflammation). Read more here.

Chongjia C Chen, Kathleen M Buchheit, Pui Y Lee, Kailey E Brodeur, Aaqib Sohail Laura Cho, Carolyn H Baloh, Barbara Balestrieri, Tahereh Derakhshan, Chunli Feng, Joshua A Boyce, Daniel F Dwyer, Tanya M Laidlaw